Streetbeat News

Analyst Ratings

KYMR

HC Wainwright & Co. analyst Andrew Fein has reiterated a Buy rating on Kymera Therapeutics (NASDAQ:KYMR) and maintained a price target of $46.

Portfolio Pulse from Benzinga Newsdesk

May 24, 2024 | 11:04 am

GGB

B of A Securities has upgraded Gerdau (NYSE:GGB) from Neutral to Buy and raised the price target from $4.5 to $5.

Portfolio Pulse from Benzinga Newsdesk

May 24, 2024 | 11:04 am

NYXH

HC Wainwright & Co. has maintained a Buy rating on Nyxoah (NASDAQ:NYXH) but lowered the price target from $22 to $18.

Portfolio Pulse from Benzinga Newsdesk

May 24, 2024 | 11:00 am

WDAY

Needham analyst Scott Berg has reiterated a Buy rating on Workday (NASDAQ:WDAY) and maintained a price target of $350.

Portfolio Pulse from Benzinga Newsdesk

May 24, 2024 | 10:57 am

CGEM

HC Wainwright & Co. analyst Edward White has reiterated a Buy rating on Cullinan Therapeutics (NASDAQ:CGEM) and maintained a price target of $28.

Portfolio Pulse from Benzinga Newsdesk

May 24, 2024 | 10:55 am

HOWL

HC Wainwright & Co. analyst Andres Maldonado has reiterated a Buy rating on Werewolf Therapeutics (NASDAQ:HOWL) and maintained a $15 price target.

Portfolio Pulse from Benzinga Newsdesk

May 24, 2024 | 10:53 am

MRUS

HC Wainwright & Co. analyst Andrew Fein has reiterated a Buy rating on Merus (NASDAQ:MRUS) and maintained a $65 price target.

Portfolio Pulse from Benzinga Newsdesk

May 24, 2024 | 10:50 am

DT

Needham analyst Mike Cikos has reiterated a Hold rating on Dynatrace (NYSE:DT).

Portfolio Pulse from Benzinga Newsdesk

May 24, 2024 | 10:45 am

SGMT

HC Wainwright & Co. has reiterated its Buy rating on Sagimet Biosciences (NASDAQ:SGMT) and maintained a price target of $32.

Portfolio Pulse from Benzinga Newsdesk

May 24, 2024 | 10:34 am

MRUS

Needham analyst Ami Fadia has reiterated a Buy rating on Merus (NASDAQ:MRUS) and maintained a $66 price target.

Portfolio Pulse from Benzinga Newsdesk

May 24, 2024 | 10:32 am